Go to Content Go to Navigation Go to Navigation Go to Site Search Homepage

CHICAGO - On Friday evening, April 21, 2023, the Supreme Court of the United States (SCOTUS) issued a decision that preserves access to the drug mifepristone, one of the two medications used in a medication abortion.  The Court ruled that access to mifepristone should remain unchanged while Alliance for Hippocratic Medicine v. FDA moves through lower courts. This decision reverses lower court decisions in recent weeks that attempted to remove or restrict access to mifepristone. 

The following statement is attributed to Jennifer Welch, President and CEO of Planned Parenthood of Illinois.

“Planned Parenthood of Illinois (PPIL) is pleased the Supreme Court issued a stay while the litigation on the federal Food and Drug Administration’s (FDA) approval of mifepristone proceeds. We can and will continue offering the safe and effective two-medication regimen of mifepristone and misoprostol. This is a win not only for PPIL patients but people across the country who deserve to have access to high-quality and effective health care including safe and legal medication abortion. 

The FDA approved mifepristone more than 20 years ago, and it has since been used by more than five million people to safely end an early pregnancy. Medication abortion with mifepristone and misoprostol is the most common abortion procedure across the nation, which means PPIL patients can continue choosing their preferred method of care.   

While this is a temporary win for abortion rights, the battle is far from over. We will continue to fight and advocate for equitable access to all reproductive and sexual health care services, because everyone should have the ability to make a decision that is best for their bodies, their lives, and their futures.”


Media Contact:
Mary Jane Maharry
[email protected]